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Abstract Immunoglobulin A (IgA) is a major
immunoglobulin isotype in the gut and plays a role in
maintenance of gut homeostasis. Secretory IgA (SIgA) has
multiple functions in the gut, such as to regulate microbiota
composition, to protect intestinal epithelium from patho-
genic microorganisms, and to help for immune-system
development. The liver is the front-line organ that receives
gut-derived products through the portal vein, implying that
the liver could be severely affected by a disrupted intestinal
homeostasis. Indeed, some liver diseases like alcoholic
liver disease are associated with an altered composition of
gut microbiota and increased blood endotoxin levels.
Therefore, deficiency of SIgA function appears as a sig-
nificant factor for the pathogenesis of liver diseases asso-
ciated with altered gut microbiome. In this review, we
describe SIgA functions on the gut microbiome and discuss
the role of IgA for liver diseases, especially alcoholic liver
disease and non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis.
Keywords IgA  ALD  NAFLD  NASH  Gut
microbiome
Introduction
The human gut microbiota, comprised of 100 trillion bac-
teria with a high diversity, has established a mutualistic
relationship with their host. While hosts provide a nutrient-
rich environment, bacteria metabolize indigested foods,
produce beneficial products like vitamins, and educate our
immune system. Although the gut microbiota homeostasis
is tightly regulated by both host and microbiota themselves,
deviation from this highly balanced condition influences
our health. A disrupted intestinal homeostasis is not only
associated with gut disorders like inflammatory bowel
diseases [1, 2] but also with extraintestinal manifestations
such as obesity [3, 4], diabetes [5, 6], autism spectrum
disorder [7, 8], and liver diseases [9–11].
To maintain the homeostasis, the gut mucosa releases
anti-microbial peptides and secretory immunoglobulins
[12]. Immunoglobulin A (IgA) is a major immunoglobulin
isotype in the gut and several grams of IgA are secreted
into the intestine each day in humans [13]. Plasma cells in
the intestinal lamina propria secrete IgA, which is tran-
scytosed across intestinal epithelial cells by a cellular
receptor, polymeric-immunoglobulin receptor (pIgR) [14].
In the gut lumen, secretory IgA controls microbiota com-
position and also serves as the first-line barrier that binds
bacteria, limits contact between bacteria and enterocytes to
prevent bacterial invasion [14–16]. Mice that lack func-
tional IgA in the gut showed altered microbial composition
and increased susceptibility to infectious diseases
[14, 17, 18]. In addition, mice carrying a genetic mutation
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Table 1 Changes in intestinal IgA associated with ALD and NAFLD/NASH in human and rodents
Human
disease/
animal
model
Subjects IgA (tissue) IgA level References
Human, alcoholics
Alcoholic
cirrhosis
Severe cirrhosis with jaundice,
compensated cirrhosis, and
control
Monomeric IgA and SIgA
(perfusion fluid of
proximal small
intestine)
Severe cirrhosis\ compensated
cirrhosis = control
[86]
Alcoholics Alcoholics with cirrhosis, alcoholics
without cirrhosis, and control
SIgA (perfusion fluid of
jejunum)
Alcoholics with/without cirrhosis = control [87]
Alcoholics Alcoholics with recent drink,
alcoholics without recent drink,
and control
Number of IgA plasma
cells (duodenum)
Alcoholics = control [88]
Amount of IgA in IgA
plasma cell (duodenum)
Alcoholics with recent drink\= alcoholics
without recent drink and control
Animal, ALD
Wister rat,
female
Intraperitoneal injection of ethanol
(4 g/kg) for 30 min
IgA-positive cells
(Peyer’s patch and
lamina propria of small
intestine)
EtOH[ saline in lamina propria,
EtOH = control in Peyer’s patch
[85]
Wister rat,
female
Intraperitoneal injection of ethanol
(4 g/kg) for 30 min, ± treatment
with NOS inhibitor
IgA-positive cells (ileal
lamina propria)
EtOH[EtOH ? inhibitor = saline [84]
Wister rat,
male
Intraperitoneal injection of ethanol
(4 g/kg) for 30 min, ± treatment
with neuronal NOS inhibitor
SIgA (ileal extract) EtOH[EtOH ? inhibitor = saline [83]
Wister rat,
male
Lieber-DeCarli liquid diet for
4 weeks
IgA-positive cells (jejunal
and colonic mucosa)
EtOH\ control [81]
C57BL/6
mouse,
female
Lieber-DeCarli liquid diet for
8 weeks
SIgA (feces) EtOH\ control [77]
C57BL/6-
Ly5.1
mouse
Lieber-DeCarli liquid diet for
10 days ? binge (5 g/kg) for 9 h
IgA-positive plasma cells
(small intestinal lamina
propria)
EtOH\ control [30]
C57BL/6
mouse
20% w/v ethanol in drinking water
for 10-12 weeks
SIgA (contents of small
and large intestine)
EtOH\ control [82]
Animal, NAFLD/NASH
Sprague–
Dawley
rat,
female
High-fat diet (88% normal ? 10%
lard ? 2% cholesterol) for
8-12 weeks
SIgA (small intestinal
mucosa)
HF =\ control in 8 weeks, HF\ control at
12 weeks
[95]
Sprague–
Dawley
rat, male
High-fat diet (30% w/w beef tallow)
for 3 weeks, ± supplied with
curcumin
SIgA (feces) HF ? curcumin[HF[LF ? curcumin = LF [92]
Sprague–
Dawley
rat, male
High-fat diet (30% w/w beef tallow)
for 3 weeks, ± supplied with
sericin
SIgA (feces and colon) HF ? sericin[HF = LF = LF ? sericin in
feces
[93]
HF ? sericin = LF ? sericin[HF = LF
Sprague–
Dawley
rat
High-fat diet (60% fat energy) for
8 weeks, ± supplied with
polyphenols
SIgA (feces) HF ? polyphenols[HF = LF [96]
C57BL/6
mouse,
male
Methionine-choline-deficient diet
for 3 weeks, ± supplied with
fructo-oligosaccharide
SIgA (feces), IgA-positive
cells (ileum and colon)
MCD\ control\MCD ? fructo-
origosaccharide (SIgA and IgA-positive cells)
[94]
SIgA secretory IgA, EtOH ethanol, HF high-fat diet, LF low-fat diet, MCD methionine-choline-deficient diet, NOS nitric oxide synthase
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in activation-induced cytidine deaminase, which cannot
undergo somatic hyper mutation and class switching to IgA
and IgG, have bacterial translocation and intestinal bacte-
rial overgrowth [19].
The liver is the front-line organ that receives and
responds to gut-derived products through the portal vein,
implying that the liver could be severely affected by the
disrupted interaction between host and gut microbiota.
Indeed, pattern-recognition receptors on Kupffer cells
respond to gut-derived bacterial components like
lipopolysaccharide (LPS) and contribute to local inflam-
mation [20]. Conversely, the liver also affects gut micro-
biota through secretion of bile, which contains bile acids
and liver-derived IgA, into the intestine. A disrupted
homeostasis in the gut has been reported to be associated
with chronic liver diseases including primary sclerosing
cholangitis, liver cirrhosis, alcoholic liver disease (ALD),
and non-alcoholic fatty liver disease/non-alcoholic steato-
hepatitis (NAFLD/NASH) [21, 22]. In this review, we will
describe the IgA function on the gut microbiome and gut–
liver axis, and discuss the potential role of IgA for liver
diseases, especially ALD and NAFLD/NASH.
Secretory immunoglobulin A in the gut
Source and function of IgA
In the intestine, naı¨ve B cells are found in the lamina
propria immediately underlying the epithelium and are
clustered in the gut-associated lymphoid follicles, such as
the Peyer’s patches (PP). By presentation of bacterial
antigens and aids from T cells in the germinal center of the
gut-associated lymphoid follicles, naı¨ve B cells are acti-
vated and become IgA-producing plasma cells. In addition,
activation of B cells was found to also occur independently
from T cells and specific antigens. In general, T cell-de-
pendent IgA production is related to higher specificity and
affinity to bacterial antigens than T cell-independent IgA
[23]. There are several extensive reviews about this B cell
activation and IgA production process in the gut [24, 25].
IgA-producing plasma cells translocate to the lamina
propria and work as a main source of the gut IgA. In the
lamina propria, plasma cells produce predominantly
dimeric IgA and the dimeric IgA is transcytosed across gut
epithelium by a membrane receptor, pIgR that is expressed
on the basolateral surface of epithelial cells. At the apical
surface of epithelial cells, the IgA-pIgR complex is cleaved
and IgA bound to an outer membrane part of pIgR, which is
known as secretory component (SC), is released as a
secretory IgA (SIgA) [14]. Although SIgA produced in the
lamina propria constitutes a major part of total IgA in the
adult gut, there are two other sources of gut IgA: maternal
milk IgA and liver-derived IgA. The milk SIgA is the only
source of IgA in the gut of newborn mammals and con-
tributes to the composition of the first gut microbiome [26],
instead of endogenous SIgA that starts to be produced
several months after birth in humans and slowly increases
[27, 28]. On the other hand, liver-derived IgA is produced
by plasma cells that colonize portal regions and the sub-
mucosa of biliary tracts, and is secreted to bile by pIgR on
hepatocytes and cholangiocytes [29, 30]. In the human
liver, however, pIgR is expressed only on cholangiocytes
[29]. The proportion of the liver-derived SIgA to total gut
SIgA varies between species: low in human and dog,
moderate in mouse, and high in rabbit and rat [29]. There is
a comprehensive review discussing liver IgA [29].
Although precise mechanisms how SIgA maintains gut
homeostasis and protects the host from pathogenic stimuli
of bacteria are not known, several mechanisms have been
suggested [14, 15]. SIgA prevents the access of bacteria to
the apical surface of epithelial cells by agglutinating bac-
teria and/or entrapping bacteria in the mucus layer.
Moreover, binding of immunoglobulins can alter gene
expression of some bacteria to reduce their virulence or
motility [31, 32]. In addition to direct effects on bacteria,
SIgA neutralizes bacterial toxins and protects epithelial
cells from the toxic stimulation [14, 15]. Meanwhile SIgA
binding inhibits bacterial access and invasion to epithelial
cells, SIgA binding to luminal bacteria also promote
sampling of the bacteria to PPs, leading to induction of a
strong response against the bacteria by B and T cells [33].
In general, SIgA exerts these functions without induction
of deleterious inflammation at the site [25]. Although
precise functions of SIgA that regulate host-microbiota
homeostasis in the gut are not well defined, deficiency of
SIgA in mice led to altered microbiome in the gut [17, 18]
and to increased susceptibility to both pathogens and toxic
reagents [17, 34].
IgA influence on gut microbiome and health
There are several genetically modified mice which lack or
have decreased SIgA in the gut lumen, and these models
allow us to investigate the role of SIgA on gut homeostasis
and host health. The effects of SIgA deficiency on models
of infectious disease have been reviewed [14]. Here, we
will focus on IgA influences on gut microbiota composition
and gastrointestinal infection of bacteria. Iga-/- mice that
lack the IgA switch region and the IgA constant region
showed altered microbiota shift from newborn to adult
[17]. Iga-/- mice showed increased and persistent colo-
nization of Enterobacteriaceae family, which is predomi-
nant ([ 75%) in newborn mice and decreased (\ 1%)
during the first 6 weeks [17]. It has been reported that the
Enterobacteriaceae bacteria family is increased in patients
J Gastroenterol (2018) 53:691–700 693
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with Crohn’s disease [2, 35], children with type 1 diabetes
[36], and cirrhotic patients [21]. In addition, Iga-/- mice
exhibited sustained intestinal inflammation and increased
susceptibility to dextran sodium sulfate (DSS)-induced
injury [17]. However, Iga-/- mice showed similar sus-
ceptibility to oral infection of Citrobacter rodentium
infection compared with wild-type mice [37].
There are two other animal models that lack SIgA in the
gut: pIgR-deficient and ‘joining’ chain (J chain)-deficient
mice. These two mice cannot properly secret IgA or IgM
into the gut lumen [14]. Decreased abundance of Bifi-
dobacterium spp., which are known as beneficial bacteria in
general, and increased abundance ofHelicobacter spp. were
observed in the cecum of the Pigr-/- mice [38]. Moreover,
the Pigr-/- mice were susceptible to Salmonella typhi-
murium infection via the fecal–oral route [39] and more
vulnerable to DSS-induced colitis than wild-type mice
[34, 38]. However, Pigr-/- exhibited similar susceptibility
to Citrobacter rodentium [37] and Clostridium difficile as
compared with wild-type mice [40]. Immunized J chain-
deficient mice were not protected from Cholera toxin [41],
while they exhibited similar clearance of Citrobacter
rodentium as wild-type mice [37]. There is no clear reason
why these mice, lacking gut SIgA, showed normal sus-
ceptibility to several bacterial infection models. It is spec-
ulated that SIgA effects on simple bacterial infection model
could be compensated by other type of immunoglobulins,
such as SIgM and IgG, and/or antimicrobial peptides.
Indeed, Iga-/- mice exhibited increased SIgM level in the
gut [42] and mRNA of antimicrobial peptides were
increased in the colon epithelium of Pigr-/- mice [38].
In humans, individuals with selective IgA deficiency
have a tendency to develop infections of the gastrointesti-
nal tract (e.g., Giardia infections), celiac disease, and
inflammatory bowel diseases [43]. Although selective IgA
deficiency showed association with these diseases, 85–90%
of IgA-deficient people are asymptomatic. However, there
are few reports investigating the characteristics of gut
microbiome of human IgA deficiency. Friman’s group
demonstrated that IgA-deficient individuals more often had
the genes involved in virulence of Escherichia coli in their
rectal flora, although only several virulent factors of E. coli
were examined [44]. Future studies that investigate IgA-
deficiency on the human gut microbiome, will be important
for this field of research.
IgA-microbiota on liver diseases
Gut microbiome-liver disease
Dietary factors including alcohol directly and indirectly
influence the gut microbiota [45–48]. Intestinal bacterial
overgrowth and bacterial dysbiosis after chronic alcohol
consumption were observed in animals and human [47].
Intragastric alcohol feeding was associated with bacterial
overgrowth in the large intestine as early as 1 week after
feeding in mice [49]. Binge drinking of alcohol leads to
elevation of blood endotoxin level. Alcohol and its
metabolite acetaldehyde disrupts tight junction of epithelial
cells and increase intestinal permeability [46]. Mice fed
with high-fat diet exhibited altered gut microbiota com-
position [50, 51] and the change was independent from
obesity [51], indicating high-fat diet itself influences gut
microbiome composition. In addition, high-fat diet
increased intestinal permeability through reduction of
tight-junction proteins and induction of intestinal inflam-
mation, leading to elevated blood endotoxin [45].
The mechanisms how altered gut microbiome contributes
to development and progression of liver diseases were pre-
viously reviewed [20, 21, 47, 48, 52, 53]. Lipopolysaccha-
ride (LPS), known as endotoxin, is a cell-wall component of
gram-negative bacteria and interacts with Toll-like receptor
4 (TLR4). As mentioned above, increased level of circulat-
ing LPS was observed in patients with ALD and rodent
models of ALD [54]. Increased endotoxin is also observed in
alcoholic patients with minimal symptoms of ALD [55] and
healthy subjects with single binge drinking [56]. In addition,
the LPS levels correlate with disease severity [57, 58]. In
mice, a LPS increase was observed both by acute binge
gavage and chronic feeding with ethanol [59]. In addition to
LPS, other bacterial components, such as bacterial 16SDNA
and peptidoglycan which is a cell-wall component of gram-
positive bacteria, were also increased in the circulating blood
[56, 60]. In general, liver-resident macrophages, Kupffer
cells, are tolerant to LPS-induced TLR4 activation and
eliminate microbial components without inflammatory
response. However, prolonged and excessive exposure to
LPS can make Kupffer cells sensitive to LPS [20]. More-
over, ethanol-induced hepatocyte damage is associated with
the liver macrophage activation through the damage asso-
ciated molecular pattern production or signaling molecule-
containing exosome production [61, 62]. Thus, sensitized
Kupffer cells by ethanol-stimulated hepatocytes respond to
gut-derived bacterial and fungal components and promote
local inflammation in the liver. Other types of microbial
products that are derived from the gut, such as bacterial DNA
and cell-wall components, are also possible mediators of
liver inflammation [20]. Recently, we found 1,3-b-glucan,
which is a cell-wall component of fungi, is also increased in
alcohol-fed mice and anti-Saccharomyces cerevisiae IgG
antibody is significantly higher in alcoholic cirrhosis
patients than in healthy individuals or viral cirrhosis patients
[63]. Translocating fungi cell-wall component promoted IL-
1b processing and local inflammation via its receptor, dec-
tin-1, on liver macrophage cells [63].
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Diet-induced endotoxemia is observed in rodent models
of obesity and NAFLD/NASH [64–67]. In humans,
NAFLD/NASH patients have higher level of systemic
endotoxin when compared with healthy people [68, 69].
Infiltration of LPS into the liver has been shown to exac-
erbate liver injury in NAFLD/NASH mice, possibly via
TLR4 activation [70]. Predisposition to obesity, which is a
common factor attributed to NAFLD/NASH development,
has been shown to be influenced by gut microbiota
[71, 72]. Germ-free mice, which do not have any
microorganisms in their body, are tolerant to high-fat diet-
induced weight gain. By transplantation of gut microbiota
from obese mice, but not from lean mice, germ-free mice
gained more fat by high-fat diet [73]. That could be
mediated by increased energy extraction from diet via
altered microbiome. In addition, the production of fasting-
induced adipocyte factor (Fiaf) is suppressed by enteric
bacteria, resulting in increased activity of lipoprotein lipase
and increased accumulation of triglycerides in the liver
[21, 71, 72]. High-fat diet altered microbiota composition
toward metabolizing dietary choline to methylamines,
resulting in reduced level of plasma phosphatidylcholine
[21, 74]. Choline-deficient diet, which also reduces phos-
phatidylcholine, is used to create rodent model of NASH.
Reduced level of phosphatidylcholine, which is necessary
for assembly of very-low-density lipoprotein (VLDL),
results in triglyceride accumulation in the liver [21]. In
addition, obese patients and children with NASH showed
increased blood ethanol concentration [10, 75]. Increased
ethanol produced by altered gut microbiome could possibly
be a mediator of liver damage [21, 52].
The role of IgA in NAFLD/NASH and ALD
IgA has been studied in the field of alcoholic liver disease
for a long time [76]. Brown and Kloppel reviewed IgA
levels in serum and the liver of ALD patients [29]. Sys-
temic IgA levels are increased in patients with alcoholic
liver disease [29] and in a rodent model of alcoholic liver
disease [77]. In addition, liver IgA deposits appear specific
for alcoholic liver disease, correlate with the amount of
alcohol consumption, but not with serum IgA concentra-
tions [78–80]. Moro-Sibilot and colleagues demonstrated
that mouse and human liver contain IgA-secreting cells.
Increased amount of IgA-secreting cells in mice fed with
ethanol was diminished by inhibition of IgA-plasmablast
egress from Peyer’s Patches with FTY720 that modulates
sphingosine-1-phosphate receptor 1 and inhibits the egress
of lymphocytes form secondary lymphoid organs, indicat-
ing that IgA deposits in the liver of ALD patients is
attributed, at least partially, to increased entry of IgA-se-
creting cells from Peyer’s Patches to the liver [30].
SIgA levels in the gut of chronic liver diseases seems
more important than systemic and liver IgA changes
because SIgA regulates gut homeostasis. Studies that
examined IgA levels in the gut of alcoholic patients and
rodent models of ALD and NAFLD/NASH are summa-
rized in Table 1. The number of IgA-secreting plasma cells
in the intestinal lamina propria [30] and fecal IgA levels
[77], which reflect the amount of colonic IgA, are reduced
in experimental models of ethanol-induced liver disease of
mice. These decreased SIgA and/or IgA-secreting cells in
the intestine are reproducibly observed in rodent models of
chronic alcohol feeding [81, 82], but not in rat model of
single administration with ethanol [83–85]. Studies inves-
tigating intestinal IgA of patients with alcoholics are very
limited [86–88]. Pelletier et al. observed decreased
intestinal secretion of SIgA in patients with severe alco-
holic cirrhosis when compared to patients with compen-
sated alcoholic cirrhosis [86]. In contrast, Colombel et al.
showed similar levels of jejunal SIgA secretion among
alcoholics with cirrhosis, alcoholics without cirrhosis, and
control subjects [87]. Maier and colleagues observed sim-
ilar number of IgA-secreting cells in duodenum between
alcoholics and controls, but a slightly decreased IgA
amount in IgA-secreting cells of alcoholics with recent
alcohol intake [88]. These conflicting reports may result
from subjects in different stages of the disease or different
methods of IgA measurement. Recently, we investigated
the role of IgA in a mouse model of ethanol-induced liver
disease by using Iga-/- mice. Unexpectedly, Iga-/- mice
fed with ethanol showed similar degrees of liver injury
(plasma ALT), hepatic triglyceride accumulation, and liver
inflammation as compared with wile-type littermates [77].
Interestingly, we observed increased bacterial translocation
to mesenteric lymph node in Iga-/- mice fed with control
diet, but no further increase of the translocation in Iga-/-
mice fed with ethanol. The result suggests that exposure of
the liver of Iga-/- mice to gut-derived bacterial component
is increased under physiological conditions and the
increased translocation is further regulated by other factors
than SIgA during disease. One possible reason why loss of
IgA did not affect disease development is a compensation
by SIgM. The Iga-/- mice fed with ethanol exhibited
increased level of fecal IgM [77]. Further studies investi-
gating compensatory roles of intestinal IgM and/or
antimicrobial peptides are necessary.
Unlike the case of ALD, reports that investigated an
association between serum IgA level and NAFLD/NASH are
limited [89–91]. Tomita et al. showed that serum IgA con-
centration is increased in severe-NASH patients when com-
pared with early-stage NASH patients, although IgA
concentrations were comparable among control, simple
steatosis, NAFLD, and early-stage NASH [89]. McPherson’s
J Gastroenterol (2018) 53:691–700 695
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group showed that serum IgA was elevated in NASH
patients as compared with simple steatosis patients [90]. In
these studies, serum IgA levels were positively associated
with severity of liver fibrosis [89–91]. However, associa-
tions between increased serum IgA and advanced stage are
also observed in other types of chronic liver diseases. Thus,
increased systemic IgA levels in NAFLD/NASH patients
may not be a specific marker for the disease progression.
Although there is no study that investigated intestinal or
fecal IgA levels of NAFLD/NASH patients, several studies
using rodent models of NAFLD/NASH showed altered
intestinal IgA secretion [92–96]. In the study of Mat-
sumoto’s group, mice with NASH induced by methionine-
choline-deficient diet, exhibited decreased fecal IgA and
IgA-positive cells in ileal and colonic tissues [94]. In
addition, Li et al. showed decreased IgA in small intestinal
mucosa of rats fed with high-fat diet, and a negative cor-
relation between the intestinal IgA levels and systemic
endotoxin levels [95]. However, similar IgA levels of feces
between high-fat and control groups or increased fecal IgA
in high-fat group were observed in several studies
[92, 93, 96]. Different feeding protocol might explain these
results. In the study from Li’s group, decreased SIgA in the
small intestine was not observe in 8-week feeding group,
but observed in 12-week feeding group [95]. Although the
mechanisms how increased systemic IgA and/or reduced
intestinal SIgA are involved in disease development and
progression are not clear yet, some gut dysbiosis and bac-
terial overgrowth observed in ALD and NAFLD/NASH
might contribute to decreased SIgA levels in the gut.
The role of SIgA on gut microbiome in NAFLD/
NASH and ALD
The study of gut SIgA functions in liver diseases is the field
that started recently, and SIgA behavior in the gut of
human alcoholic patients has not been intensively investi-
gated yet. However, several studies revealed shared fea-
tures of gut microbiome changes between SIgA-deficient
mice and human patients with alcoholic liver disease. As
mentioned above, Iga-/- mice exhibited increased colo-
nization of Enterobacteriaceae family (in phylum Pro-
teobacteria) [17]. Increased abundance of phylum
Proteobacteria is a signature of intestinal dysbiosis asso-
ciated with metabolic and inflammatory diseases [97].
Moon et al. found dichotomous fecal IgA levels among
wild-type mice in the same facility and the IgA-low phe-
notype was driven by transmissible fecal bacteria [98]. This
IgA-low phenotype of mice was associated with enriched
Enterobacteriaceae family. Although increased Enterobac-
teriaceae family was not observed in IgA-low mice from a
different facility in the same study, the phylum Pro-
teobacteria was increased in the mice [98]. These results
indicate decreased SIgA may drive the expansion of
Enterobacteriaceae family (or phylum Proteobacteria) in
the gut of chronic liver diseases, such as ALD and NAFLD/
NASH. Increased members of the Enterobacteriaceae
family or phylum Proteobacteria is also observed in
chronic liver diseases [21]. Zhu et al. and colleagues
revealed that abundance of Escherichia spp. (in Enter-
obacteriaceae family) and Enterobacteriaceae family are
increased in stool of children with NASH when compared
with healthy children or children with obesity [10].
Increased Gammmaproteobacteria class, which includes
Enterobacteriaceae family, was also observed in children
with NAFLD when compared with healthy children in a
different study [99]. A study in which gut microbiota
composition were compared between 53 NAFLD patients
and 32 healthy subjects showed increased Escherichia spp.
in NAFLD patients [100]. Increased abundance of phylum
Proteobacteria and/or Enterobacteriaceae family were
reproduced in rodent models of NAFLD [101–104].
However, the enrichment of Enterobacteriaceae and
Escherichia spp. was not reproduced in human studies
[105, 106]. Taken together, decreased amount of SIgA in
the gut lumen, which was observed in rats fed with high-fat
diet [95], may contribute to expansion of phylum Pro-
teobacteria and/or Enterobacteriaceae family of bacteria
and disease pathogenesis.
The prominent feature of dysbiosis observed in alco-
holic patients and rodent model of alcoholic liver disease is
characterized by a decreased phylum Firmicutes and lower
amount of Lactobacillus spp. (in phylum Firmicutes)
[49, 107–110]. Probiotic treatment with Lactobacillus spp.
and Bifidobacterium spp. improved bacterial dysbiosis and
ameliorated liver injury and/or inflammation in both
humans and animal models (previously reviewed by
Bluemel et al. [111]). In addition to these bacteria, alco-
holic patients with dysbiosis showed a higher relative
abundance of Gammmaproteobacteria class (in phylum
Proteobacteria) than alcoholic patients without dysbiosis
[112]. Relative abundance of Enterobacteriaceae family
was higher in the stool of patients with alcohol hepatitis
than alcoholic patients without hepatitis [113]. Increased
Enterobacteriaceae is reproducibly observed in human
cirrhotic patients [9, 11, 114]. Bajaj et al. proposed the
cirrhosis dysbiosis ratio (CDR). The ratio of ‘‘good’’ bac-
teria, such as Lactobacillus spp., against potentially ‘‘bad’’
bacteria, such as Enterobacteriaceae was lower in advanced
cirrhotic patients as compared with that in compensated-
cirrhotic patients [58]. Especially, cirrhotic patients with
alcoholic etiology showed increased Enterobacteriaceae
696 J Gastroenterol (2018) 53:691–700
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family [58]. Although these facts suggest a possible link
between reduced SIgA and development of the disease,
studies investing direct effects of SIgA on the diseases are
limited. Further studies investigating the change of gut
microbiome and disease status in SIgA-deficient mice are
required.
Fc receptor alpha I and IgA on liver diseases
In addition to the SIgA roles in the intestinal lumen, it has
been suggested that serum and lamina propria IgA play a
role in mucosal immunity via binding to a transmembrane
receptor, Fc receptor alpha I (FcaRI) [115]. Functions of
FcaRI are previously reviewed [115, 116]. FcaRI is
expressed on cells of the myeloid lineage, including neu-
trophils, eosinophils, and Kupffer cells [116]. In contrast to
non-inflammatory functions of SIgA, serum monomeric
IgA and dimeric IgA (dIgA) in the lamina propria can
induce several pro-inflammatory functions via the binding
to FcaRI [115]. Cross-linking of FcaRI by IgA immune
complexes (e.g., IgA-coated bacterial cells) mediates the
production of reactive oxygen species and lymphokine
from neutrophils and promotes phagocytosis by neutrophils
and Kupffer cells [115, 117]. However, studies investi-
gating this topic are lacking, because mice do not have an
equivalent receptor of the human FcaRI [118].
Egmond’s group revealed serum IgA to eliminate bac-
teria invading the liver, by using mice with a transgene that
is introduced with a cosmid clone containing the human
FcaRI gene [117]. Kupffer cells that express the human
FcaRI effectively phagocytosed bacteria coated with serum
IgA, but not with SIgA. In contrast, the number of
phagocytosed bacteria in the liver of non-transgenic mice
were only 20% of that of the transgenic mice [117]. In
addition, neutrophils isolated from healthy human donors
responded to serum IgA and produce leukotriene B4
(LTB4), leading to further recruitment of neutrophils [119].
Mouse neutrophils that express human FcaRI phagocy-
tosed IgA-coated bacteria more than BSA-coated bacteria.
In the colon of patients with ulcerative colitis, a number of
FcaRI-expressing neutrophils infiltrated the lamina propria
and phagocytosed IgA-complexes. In contrast, few neu-
trophils were observed in the colon of healthy subjects
[119]. These results indicate that IgA opsonizes bacteria
and promotes effective phagocytosis of and elimination of
the invading bacteria via binding to FcaRI on phagocytes.
Thus, serum IgA and lamina propria dIgA can work as
second line barrier against translocated bacteria from the
gut lumen to lamina propria, portal blood, and the liver
which is observed in patients with ALD and NAFLD/
NASH. However, excessive activation of this function
potentially can lead to local inflammation. There is no
study investigating the role and expression of FcaRI in the
liver and/or gut of patients with ALD and NAFLD/NASH
and of animal models. These studies are necessary to
understand the precise role of IgA on pathogenesis of
diseases.
Future directions
The intestinal microbiome has been suggested to contribute
to the development and progression of ALD and NAFLD/
NASH. However, precise mechanisms how the gut
microbiome contributes to the disease pathogenesis and
how the development of diseases disrupts gut homeostasis
are not fully understood. Some features of altered gut
microbiome, such as increased phylum Proteobacteria and
Enterobacteriaceae family of bacteria, are shared between
IgA-deficient animals and patients with and animal models
of ALD and NAFLD/NASH. In addition, chronic feeding
of alcohol and an obesogenic diet causing NAFLD/NASH
led to decreased intestinal production of IgA in rodents.
These facts imply the potential role of SIgA on the liver
diseases. However, there are limited studies that investigate
SIgA change in patients and reveal direct influence of IgA-
deficiency on development of ALD, NAFLD or NASH.
These studies are necessary in the future.
In addition to SIgA in the gut homeostasis, the role of
circulating IgA, which is increased in ALD and NASH
with cirrhosis, also requires to be investigated in future
studies. It has been suggested that FcaRI on Kupffer cells
and neutrophils contribute to elimination of gut-derived
bacteria and its products via activating phagocytosis.
However, it has been difficult to investigate the role of
IgA-FcaRI in development of the liver diseases because
mice lack equivalent receptor of human FcaRI. To apply
the transgenic mice introduced with the human FcaRI gene
to investigate the role could be a solution of the problem.
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